Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00877669
Other study ID # 2008-10-038
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2008
Est. completion date December 2016

Study information

Verified date November 2019
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare of Efficacy and Safety Between Holmium Laser Enucleation of the Prostate (HoLEP) and Transurethral Resection of the Prostate (TURP) on the Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostate Hyperplasia (BPH).


Recruitment information / eligibility

Status Completed
Enrollment 313
Est. completion date December 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender Male
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria:

- 50 yrs or greater

- International prostatic symptom score >= 12

- Bladder outlet obstruction confirmed by pressure-flow study (BOOI > 20)

- Able to give fully informed consent

Exclusion Criteria:

- Patients with urologic malignancies such as prostate cancer and bladder cancer

- Patients underwent urethral, prostate surgery

- Patients with urethral stricture or bladder diverticulum or bladder neck contracture

- Patients with histories of bacterial prostatitis within 1 year

- seems not to be appropriate to this study by the decision of investigators because of any other reasons

Study Design


Intervention

Procedure:
Transurethral resection of the prostate
Standard transurethral resection of the prostate using electrocautery loop
Holmium Laser Enucleation of the Prostate
HoLEP using 100W Ho:YAG laser

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The changes of International Prostatic Symptom Scores (IPSS) from baseline to 6 months after operation 6 months
Secondary The changes of Quality of Life (QoL) parameters 6 months
Secondary The changes of IPSS and QoL parameters 1 month and 3months after operation
Secondary The changes of Uroflowmetry (UFM) and Postvoid residual urine(PVR) parameters 2 weeks and 3 and 6 months after operation
Secondary Postoperative hospital stay days and postoperative catheterization days immediate postoperative period
Secondary The changes of the hemoglobin and the serum sodium 0 and 1 day after operation
Secondary Operative time and Resected tissue weight 0 day after operation
Secondary The changes of ICS male questionnaire (short form) parameters 3 and 6 months after operation
Secondary The changes of international index of erectile function (IIEF)-15 parameters 6 months after operation
Secondary The changes of Patient perception of treatment benefit questionnaire (PPTB) parameters 3 and 6 months after operation
Secondary The changes of voiding frequencies and urgency parameters in Frequency volume chart 3 and 6 months after operation
Secondary Ejaculation parameter 6 months after operation
Secondary Complications During all study periods
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Recruiting NCT04853914 - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound. N/A